August tends to be a somewhat less busy time in terms of patent office output. So we have only three international applications to report this time: INT-131, a PPAR modulator, for multiple sclerosis; ultra-low dose naltrexone for many disorders with neuropsychiatric context; and thalidomide for aging diseases. https://www.hmpharmacon.com| office@hmpharmacon.com| Twitter: https://twitter.com/hmpha...

Efforts towards finding new uses for known, discontinued or candidate drugs never abate. And while patent examiners might take the occasional summer break the PCT publishing outlet discharges a steady stream of documents. In the second half of July (the first two weeks were "dry" as far as repurposing is concerned) we noted Novartis claiming its α7 nicotinic receptor agonistcandidatedrug, AQW051 f...

We conclude our discussion of drug repurposing patents published in June 2014 with patent applications for repurposing candidates that could not be further apart in price (GM-CSF and Aspirin); an immunomodulatory dipeptide; and yet another NSAID for Alzheimer's disease.For those who can and will take a few days off -- enjoy!https://www.hmpharmacon.com| office@hmpharmacon.com| Confidential communit...

We continue to present recent international patent applications that tap into the universe of pharmacologically active compounds - in development, marketed, proprietary, generic, successful or failed - to find new medical uses for molecules that are already known. As this database grows, its areas of overlap with our Discontinued Drug Database - which goes back to the early 1990s - develop in numb...

On July 15th H.M Pharma Consultancy's CEO Hermann Mucke presented patent analysis data at Arrowhead's 3rd Annual Drug Repositioning, Repurposing and Rescue Conference in Boston. One of the most interesting results was that the most frequent applicants filing drug repurposing patents published between January 2012 and April 2014 were European, while the general interesting pharma patents had the U....

Sorry Ladies and Gentlemen for our two months of silence. We had business to conduct like you won't believe... actually couldn't spare the few hours per month that it takes writing these commentaries. OK, we are still extremely busy... but this little blog is back again. In order to catch up we will shorten the commentaries a bit, and present them in much more rapid succession.On July 15th H.M Pha...

Once again, the past month has seen so many published international applications related to drug repurposing that we have to split or report in twain. Here are four examples from the first half of April.H.M Pharma Consultancy is the Knowledge Foundry, and not only for drug repurposing -- see our website, below. If you think that we might be able to help you with a project, please contact us.https...

The preparations for launching the journal, Drug Repurposing, Rescue, and Repositioning slowly heat up, while the examiners at the patent offices as well as the publication division of the WIPO simply carry on; making sure that our clever wetware search algorithms never run out of new repurposing patent applications. For March 2014 we present: old drugs that could be cognition boosters under cert...

This continues the discussion of documents published in February 2014, an incredible month in terms of patenting in this field. This time we present: a dopamine agonist delivered transdermally for headaches; endothelin receptor blockers, marketed for pulmonary hypertension, might be repurposed for cognitive impairment and Alport syndrome; the hypertension drug telmisartan act against demyelinatin...

Too much! Or more precisely, too many. February 2014 has been so studded with international drug repurposing patent applications that we have to split the discussion. For starters, we present: rebamipide for dyslipidemia; cyclodextrins as drugs in their own right, for lysosomal storage diseases; new facettes of the old anti-helminthic, niclosamide in cancer; and an adenosine A3 receptor agonist t...